Heart drug gets a second chance: new study tests Re-Treatment
NCT ID NCT07213583
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times
Summary
This study tests whether giving ALXN2220 again can help people with a rare heart condition called transthyretin amyloid cardiomyopathy. About 35 people who already received the drug once will get a second round. Researchers will check heart function and safety over 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID TRANSTHYRETIN CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse - Hôpital Rangueil
Toulouse, 31059, France
-
CHU de Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222, Spain
-
Hôpital Henri Mondor
Créteil, 94000, France
-
University Medical Center Groningen
Groningen, 9713, Netherlands
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.